Chart Review of Antivirals for Influenza in Infants
A Retrospective Chart Review to Assess the Safety of Oseltamivir (Tamiflu®) Compared to Alternate Antiviral Therapy (Amantadine or Rimantadine) Administered to Children Less Than 12 Months of Age With Diagnosed or Suspected Influenza (CASG 113)
This retrospective study conducted in Canada and the US involves a chart review to assess the safety of oseltamivir (Tamiflu®) compared to alternate antiviral therapy, amantidine or rimantidine, administered to children less than 12 months of age with diagnosed or suspected influenza.
The objectives are to describe the frequency of neurological and all other adverse events possibly related to administration of these antivirals in these infants.
Investigators will also compare frequency of adverse events at various doses of oseltamivir in these children.
Critical endpoints to be collected include frequency and severity of adverse events, particularly those relating to central nervous system complications.
A sub-investigator will travel to each of the participating sites to collect data related to each infant's health prior to becoming ill, health status at time of influenza diagnosis, dosing regimen, reported neurological events post-dosing, and all reported adverse events post-dosing.
研究概览
地位
完全的
条件
详细说明
The study is a retrospective review of charts of children less than 12 months of age that were diagnosed with influenza and treated with oseltamivir.
The chart review will focus on assessment of neurological and other adverse events that may have been related to the administration of oseltamivir.
A control population will consist of children less than 12 months treated with either rimantadine or amantadine.
The administration of oseltamivir to children at high risk (i.e.
immunocompromised hosts) less than 12 months old with influenza is frequently considered in medical practice despite the findings of neurotoxicity in a juvenile rat study.
Since oseltamivir is the only active treatment against H5N1 influenza strains, it is imperative to understand the ramifications of its potential widespread use in very young infants in the event of an outbreak.
This study is designed to gather documented evidence by which the circumstances of use and defined outcomes can be described.
Patient selection will be made by review of hospital inpatient medical records, emergency room medical records and/or pharmacy records to identify patients less than 1 yr old dosed with oseltamivir suspension.
Redacting the charts will be done in a manner that will obscure personal health information (individual identifiers) without obscuring the necessary clinical data.
A separate research data collection form will be prepared on which critical information can be transcribed that would subsequently be available for analysis.
Critical information to be captured at the time of initiating oseltamivir treatment includes: age, birth history, gender, underlying medical conditions, presenting influenza symptoms, if done, type of flu test and dose regime.
Critical endpoints to be collected will include the frequency and severity of adverse events, particularly those relating to central nervous system complications.
研究类型
观察性的
注册
200
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 2B7
- University of Alberta
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233-0011
- University of Alabama at Birmingham
-
-
Arkansas
-
Pulaski、Arkansas、美国、72202
- Arkansas Children's Hospital
-
-
California
-
Orange、California、美国、92868
- Children's Hospital of Orange County
-
San Diego、California、美国、92123
- Children's Hospital and Health Center
-
-
Colorado
-
Denver、Colorado、美国、80218
- University of Colorado
-
-
Missouri
-
Saint Louis、Missouri、美国、63110
- Washington University in St. Louis
-
-
Nebraska
-
Omaha、Nebraska、美国、68198-2162
- Creighton University
-
-
Ohio
-
Cleveland、Ohio、美国、44109
- MetroHealth Medical Center
-
-
Oregon
-
Portland、Oregon、美国、97201-3098
- Oregon Health Sciences University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas、Texas、美国、75390-9063
- The University of Texas Southwestern Medical Center
-
Fort Worth、Texas、美国、76104
- Cook Children's Medical Center
-
San Antonio、Texas、美国、78229-3900
- The University of Texas Health Science Center
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- University of Utah
-
-
Washington
-
Seattle、Washington、美国、98105
- Seattle Children's Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
不超过 11个月 (孩子)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Male or female study participants less than 12 months of age
- Suspected or laboratory diagnosis of influenza
- Treated with oseltamivir, rimantadine or amantadine
Exclusion Criteria:
None listed
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2005年11月1日
研究完成
2006年12月1日
研究注册日期
首次提交
2006年4月5日
首先提交符合 QC 标准的
2006年4月5日
首次发布 (估计)
2006年4月6日
研究记录更新
最后更新发布 (估计)
2011年5月13日
上次提交的符合 QC 标准的更新
2011年5月12日
最后验证
2007年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.